Does gastrointestinal Candida albicans prevent ubiquinone absorption?

Area of Science:

• Biochemistry
• Human Physiology
• Medical Mycology

Background:

• Ubiquinones, such as coenzyme Q (CoQ), are vital for cellular energy production (oxidative phosphorylation) in both humans and yeasts.
• Coenzyme Q10 (CoQ10) is a commonly administered oral supplement for treating various conditions, including heart disease.
• Significant variability exists in patient responses to CoQ10 therapy, with some requiring higher doses to achieve therapeutic blood levels.

Purpose of the Study:

• To investigate the hypothesis that Candida colonization in the gastrointestinal (GI) tract may explain the variability in patient response to CoQ10 supplementation.
• To explore whether the yeast Candida albicans utilizes supplemental CoQ10, thereby reducing its bioavailability for the human host.

Main Methods:

• A pilot study involving in vitro experiments with two pathogenic strains of Candida albicans.
• Analysis of data from a single patient case study.

Main Results:

• Preliminary data from one patient and in vitro studies suggest that Candida albicans can uptake and utilize supplemental CoQ10.
• This utilization by yeast may lead to diminished CoQ10 availability for the human subject.

Conclusions:

• Candida colonization of the GI tract is a potential factor contributing to the variable efficacy of CoQ10 therapy.
• Medical treatments that increase the risk of Candida colonization, such as antibiotics, may exacerbate this issue.
• The findings suggest that GI Candida overgrowth could have clinical implications for patients relying on CoQ10 supplementation.